


Specialty Platelet Testing

Platelets are the intended, and sometimes unintended, targets of countless therapeutics. There is also an increasing appreciation that pathologies such as coronary artery disease, diabetes, and cancer alter platelet function. As such, consideration of platelet function is essential throughout pharmacologic development. At MLM, our expertise in specialty platelet testing will complement your drug discovery, preclinical testing, and clinical trials. Our highly trained research and project management team will work with you to solve your challenges, identify on-site or specialty central lab testing options, or customize methodology and logistics, if necessary, to suit your needs.

MLM offers a panel of specialty platelet tests as well as nearly three decades of expertise in the area of platelet biology to support your translational and clinical research needs.



* Proprietary methodologies developed at MLM, adapted for clinical studies
 † Complementary biomarker testing available

Platelet function testing is performed using relevant state-of-the-art technology including multi-color flow cytometry, light transmission aggregometry, lumiaggregometry, and point-of care equipment, as applicable. In addition to prototypical platelet activation assessment (e.g., GPIIb-IIIa, P-Selectin) MLM offers specialty testing formats and assay development tailored to your project needs. Previous custom method development has included stabilizing patient samples at clinical sites for shipment and in-house testing or full-scale assay development to directly measure novel components of platelet function.

Platelet Research Assets	In Vitro, Pre-Clinical & Clinical Expertise
<ul style="list-style-type: none"> Multi-color flow cytometry Light transmission and luminescence aggregometry Companion biomarker testing Project team includes a dedicated project scientist, technical staff, QAU, operations oversight, and project management 	<ul style="list-style-type: none"> <i>In-vitro</i> and preclinical models and testing CLIA-approved laboratory Access to normal/disease-specific donors Therapeutic experience includes small molecules, peptide and nonpeptide-based therapies, and nutraceuticals Experienced in early to late-phase clinical trials